Claims
- 1. An amide of formula I:
- wherein:
- E is nitrogen;
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2 k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring;
- X is ArY;
- Y is a linking group selected from carbonyl, sulfinyl, and sulfonyl; and
- Ar is phenyl substituted with 0-2 substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, and (1-4C)alkoxy; provided that the 4-position of said phenyl may be substituted by fluoro only, and that the said phenyl may not be 3,5-disubstituted; and provided that Ar is not 3-chlorophenyl, 3-bromophenyl, 3-iodophenyl, or 3-(1-4C)alkylphenyl when Y is carbonyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 2. An amide as claimed in claim 1, wherein Ar is selected from phenyl, 2-, 3- and 4-fluorophenyl, 2- and 3-chlorophenyl, 2- and 3-cyanophenyl, 2- and 3-hydroxyphenyl, 2- and 3-methoxyphenyl, and 2- and 3-methylphenyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 3. An amide as claimed in claim 2 wherein Y is carbonyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 4. An amide as claimed in claim 2 wherein Y is sulfinyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 5. An amide as claimed in claim 2 wherein Y is sulfonyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 6. A pharmaceutical composition comprising an amide of formula I: ##STR3## wherein: E is nitrogen;
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon
- atoms in said ring;
- X is ArY;
- Y is a linking group selected from carbonyl, sulfinyl, and sulfonyl; and
- Ar is phenyl substituted with 0-2 substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, and (1-4C)alkoxy; provided that the 4-position of said phenyl may be substituted by fluoro only, and that the said phenyl may not be 3,5-disubstituted; and provided that Ar is not 3-chlorophenyl, 3-bromophenyl, 3-iodophenyl, or 3-(1-4C)alkylphenyl when Y is carbonyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester; and a pharmaceutically acceptable diluent or carrier.
- 7. A method of treating urinary incontinence, comprising administering to a mammal in need of such treatment an effective amount of an amide of formula I: ##STR4## wherein: E is nitrogen;
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring;
- X is ArY;
- Y is a linking group selected from carbonyl, sulfinyl, and sulfonyl; and
- Ar is phenyl substituted with 0-2 substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, and (1-4C)alkoxy; provided that the 4-position of said phenyl may be substituted by fluoro only, and that the said phenyl may not be 3,5-disubstituted; and provided that Ar is not 3-chlorophenyl, 3-bromophenyl, 3-iodophenyl, or 3-(1-4C)alkylphenyl when Y is carbonyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9116069 |
Jul 1991 |
GBX |
|
9209416 |
Apr 1992 |
GBX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/329,188 filed on Oct. 26, 1994, now U.S. Pat. No. 5,474,999; which is a divisional of U.S. application Ser. No. 08/126,350, filed Sep. 24, 1993, now U.S. Pat. No. 5,382,598; which is a divisional of U.S. application Ser. No. 07/918,982, filed Jul. 23, 1992, now U.S. Pat. No. 5,272,163.
US Referenced Citations (13)
Foreign Referenced Citations (8)
Number |
Date |
Country |
0181568 |
May 1986 |
EPX |
0189142 |
Jul 1986 |
EPX |
0253503 |
Jan 1988 |
EPX |
0274867 |
Jul 1988 |
EPX |
0409414 |
Jan 1991 |
EPX |
0409413 |
Jan 1991 |
EPX |
7008629-Q |
Jun 1969 |
NLX |
7008627-Q |
Jun 1969 |
NLX |
Non-Patent Literature Citations (2)
Entry |
R Bayles et al., "The Smiles rearrangement of 2-aryloxy-2-methylpropanamides. Synthesis of N-aryl-2-hydroxy-2-methylpropanamides" Synthesis. (1977), 31-33. |
G Edwards et al., "Structure-activity relationships of potassium channel openers", Trends in Pharmacological Sciences. (1990), 11, 417-422. |
Divisions (3)
|
Number |
Date |
Country |
Parent |
329188 |
Oct 1994 |
|
Parent |
126350 |
Sep 1993 |
|
Parent |
918982 |
Jul 1992 |
|